BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax of $3.13 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2015-09-30 was $3.13M, a 68.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2015-06-30 was -$2.71M, a 198.94% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2015-03-31 was $13.78M, a 531.06% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for the quarter ending 2014-12-31 was $4.60M, a 529.41% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2014 was $19.29M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, before tax for fiscal 2013 was -$2.15M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax 12 month |
|---|---|---|---|---|
| 2015-09-30 | $3.13M 10-Q · filed 2015-11-02 | $415.00K derived: sum of 2 quarters · filed 2015-11-02 | $14.19M 10-Q · filed 2015-11-02 | $18.79M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | -$2.71M 10-Q · filed 2015-08-05 | $11.06M 10-Q · filed 2015-08-05 | $15.67M derived: sum of 3 quarters · filed 2015-08-05 | $25.43M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-03-31 | $13.78M 10-Q · filed 2015-05-05 | $18.38M derived: sum of 2 quarters · filed 2015-05-05 | $28.14M derived: sum of 3 quarters · filed 2015-11-02 | $30.89M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $14.37M derived: sum of 2 quarters · filed 2015-11-02 | $17.11M derived: sum of 3 quarters · filed 2015-11-02 | $19.29M 10-K · filed 2015-03-02 |
| 2014-09-30 | $9.77M 10-Q · filed 2015-11-02 | $12.51M derived: sum of 2 quarters · filed 2015-11-02 | $14.69M 10-Q · filed 2015-11-02 | $15.42M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-06-30 | $2.74M 10-Q · filed 2015-08-05 | $4.92M 10-Q · filed 2015-08-05 | $5.65M derived: sum of 3 quarters · filed 2015-08-05 | $2.38M derived: sum of 4 quarters · filed 2015-08-05 |
| 2014-03-31 | $2.18M 10-Q · filed 2015-05-05 | $2.91M derived: sum of 2 quarters · filed 2015-05-05 | -$364.00K derived: sum of 3 quarters · filed 2015-05-05 | -$1.03M derived: sum of 4 quarters · filed 2015-05-05 |
| 2013-12-31 | $731.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$2.55M derived: sum of 2 quarters · filed 2015-03-02 | -$3.22M derived: sum of 3 quarters · filed 2015-03-02 | -$2.15M 10-K · filed 2015-03-02 |
| 2013-09-30 | -$3.28M 10-Q · filed 2014-10-28 | -$3.95M derived: sum of 2 quarters · filed 2014-10-28 | -$2.89M 10-Q · filed 2014-10-28 | |
| 2013-06-30 | -$670.00K 10-Q · filed 2014-07-31 | $392.00K 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | $1.06M 10-Q · filed 2014-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |